|Dear Medprax Clients
The 2021 Master Industry Table for ICD 10 Codes have been published to accommodate more ICD 10 Codes for Covid 19 and any other future diseases of uncertain etiology.
Here is the shortlist of new valid clinical and primary ICD 10 codes added for 2021:
New pill with ingestible microchip monitors you from the inside
** With courtesy: TechRepublic
By Janet Fang | January 17, 2012, 11:24 PM PST
Soon, patients will be able to buy smart pills that have tiny ingestible sensors that can help track their medication use. Um, the call is coming from inside the house?
Patients not taking their meds as prescribed cost the US $290 billion in increased medical costs.
And last week, Silicon Valley’s Proteus Biomedical announced the launch of their ‘digital health product’ in the UK, in collaboration with pharmacy chain Lloydspharmacy.
“The most important and basic thing we can monitor is the actual physical use of the medicine,” says Andrew Thompson of Proteus Biomedical.
These ‘sensor-enabled tablets’ are called Helius, and they come with ‘ingestible event markers.’ These can be taken with pills or incorporated directly into medicines by the manufacturers. The sensors are embedded in a placebo to be taken alongside the actual meds.
The sensors are activated by stomach acid, and as Nature News explains, they’re powered much like potato batteries (where 2 different metals generate a current when inserted into the tuber).
Each sensor – about the size of a grain of sand – contains a tiny amount of copper and magnesium. When you swallow one of these devices, you become the potato that creates a voltage. That then is used to power the device, which creates a signal.
The digital signal can’t be detected except by an adhesive patch attached to your skin, like a bandage.
It monitors things like heart rate, respiration, temperature, body posture, and even sleeping patterns – to show how you’re responding to the medication.
These data are then relayed to your cellphone to be shared with whomever you like. Your doctor might decide to change dosages or medication based on that info.
The cost of the monitoring service is slated to be £50 ($77) a month. Lloydspharmacy hopes to make the system available in September.
Proteus Biomedical is developing and commercializing a range of digital health care products with others in the industry, such as Novartis, Medtronic, ON Semiconductor, and Kaiser Permanente. The company has already tested the system in hundreds of patients in many different therapeutic areas: tuberculosis, mental health, heart failure, hypertension, and diabetes.
Wonder what effect this will have on our dentists using Kodak equipment and software at their practices.
“Photography and camera giant Kodak has finally filed for bankruptcy protection in the United States, following months of speculation.
“The board of directors and the entire senior management team unanimously believe this is a necessary step and the right thing to do for the future of Kodak,” chairman and chief executive Antonio M Perez said in a statement.
Kodak announced the company, and its subsidiaries, had filed for Chapter reorganisation but that international subsidiaries and entities were not impacted.
The company has attempted to restructure its business for quite some time. Although it has focused more on printers and, the downturn in traditional photography has hurt the company.
The bankruptcy provision would assist the company to use its patents, according to its announcement.”
Medical Aid Industry to Collapse?
BHF head warns on SA medical aid sector
PUBLISHED: 28 OCTOBER 2015
The medical aid industry is in trouble, and if nothing is done, it will collapse, forcing millions of members to turn to the public healthcare sector, warns a leading medical executive. The industry has been paying out more than it collects from members. And, on top of that, contributions have been increasing at a pace that is 50% higher than the inflation rate, while benefits have been shrinking.
City Press reports that it is this lethal combination that makes the CEO of the Board of Healthcare Funders, Humphrey Zokufa, believe that medical aid schemes are at risk of collapsing. “What we are seeing right now is that schemes are paying out more than they collect per annum. Some schemes are even using their reserves to pay for claims. “This is not an ideal situation and it is not sustainable in the long term,” said Zokufa.
The Board of Healthcare Funders represents the interests of 65% of the country’s medical aid schemes, but works with most of them in one way or another. Zokufa explained that when schemes paid out more than they collected, premiums were bound to go up. “This is what we have been seeing in the past couple of years, with schemes increasing their premiums far higher than the inflation rate. Medical schemes are trying to match what they pay out. The downside to this is that when premiums increase, it’s the members who suffer,” he said.
Elsabé Conradie, GM of stakeholder relations at the Council for Medical Schemes, agreed, saying that members were the ones who bore the burden of hefty annual increases. She explained that the reason medical aid premiums were escalating every year was primarily because of the high prices charged by service providers, mainly specialists. She also cited the decline in the number of young, healthy people signing up for medical aid schemes. This group usually cross-subsidises the old and sick members of a medical aid scheme.
Zokufa also pinned the blame on specialists and private hospitals, as both were claiming exorbitant amounts from medical aids. “Specialists and private hospitals have free rein in this country. They charge whatever they want because their prices are not regulated,” he said. “When you look at private healthcare expenditure in the last 10 years, you will see that 60% of the budget goes to specialists and private hospitals, while general practitioners and other entities share the remainder of the pie. This situation is not healthy or adequate because it fuels the contribution increases and impacts on the money paid by members to cover the shortfall on their medical bills,” he said.
Believes the judgment is bad news for consumers.
The Board of Healthcare Funders (BHF) will appeal against a court ruling that requires medical aids to pay in full for prescribed minimum benefits’ (PMB) conditions.
“The BHF believes the judgment is bad news for consumers, as the uncertainty with regards to pricing of healthcare will continue,” it said in a statement on Thursday.
On Monday, the High Court in Pretoria ruled that PMBs, which protect members of medical schemes, must remain in place.
The BHF was one of the respondents in the case.
It was hoping the court would give a clear understanding of the implications of regulation eight of the Medical Schemes Act 131 of 1998.
The regulation states that medical schemes must pay for the diagnosis, treatment and care of all PMB conditions in full, or at the price charged by the health care provider.
Therefore, private healthcare providers, could for example, inflate their prices with the knowledge that it exceeded costs that might be incurred by government hospitals, clinics and the like.
The industry body said it would appeal the ruling as the principles and merits of the matter did not appear to have been considered.
“We believe that this judgment may negatively affect the sustainability of medical schemes, which have been under severe financial pressure due to the opportunistic and reckless charging by some healthcare providers for PMB.”
It said it was concerned that medical schemes may have no choice but to raise contribution premiums and this would affect its members.
“Over the past few years, the healthcare provider fraternity has been partly or fully responsible for the scrapping of all healthcare pricing guidelines and undermining the coding structure.”
This had increased costs within the private healthcare sector.
“We believe that the judgment will allow this untenable situation to continue,” said the BHF.
*** FROM MONEYWEB 10 NOV 2011